Cargando…

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

Phosphatidylinositol 3-kinase signaling promotes cell growth and survival and is frequently activated in infiltrative gliomas. Activating mutations in PIK3CA gene are observed in 6–15% of glioblastomas, although their clinical significance is largely undescribed. The objective of this study was to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Shota, Batchelor, Tracy T., Iafrate, A. John, Dias-Santagata, Dora, Borger, Darrell R., Ellisen, Leif W., Yang, Daniel, Louis, David N., Cahill, Daniel P., Chi, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487518/
https://www.ncbi.nlm.nih.gov/pubmed/31036078
http://dx.doi.org/10.1186/s40478-019-0720-8
_version_ 1783414513921425408
author Tanaka, Shota
Batchelor, Tracy T.
Iafrate, A. John
Dias-Santagata, Dora
Borger, Darrell R.
Ellisen, Leif W.
Yang, Daniel
Louis, David N.
Cahill, Daniel P.
Chi, Andrew S.
author_facet Tanaka, Shota
Batchelor, Tracy T.
Iafrate, A. John
Dias-Santagata, Dora
Borger, Darrell R.
Ellisen, Leif W.
Yang, Daniel
Louis, David N.
Cahill, Daniel P.
Chi, Andrew S.
author_sort Tanaka, Shota
collection PubMed
description Phosphatidylinositol 3-kinase signaling promotes cell growth and survival and is frequently activated in infiltrative gliomas. Activating mutations in PIK3CA gene are observed in 6–15% of glioblastomas, although their clinical significance is largely undescribed. The objective of this study was to examine whether PIK3CA mutations are associated with a specific clinical phenotype in glioblastoma. We retrospectively reviewed 157 consecutive newly diagnosed glioblastoma patients from December 2009 to June 2012 who underwent molecular profiling consisting of targeted hotspot genotyping, fluorescence in situ hybridization for gene amplification, and methylation-specific PCR for O(6)-methylguanine-DNA methyltransferase promoter methylation. Molecular alterations were correlated with clinical features, imaging and outcome. The Cancer Genome Atlas data was analyzed as a validation set. There were 91 males; median age was 58 years (range, 23–85). With a median follow-up of 20.9 months, median progression-free survival (PFS) and estimated overall survival (OS) were 11.9 and 24.0 months, respectively. Thirteen patients (8.3%) harbored PIK3CA mutation, which was associated with younger age (mean 49.4 vs. 58.1 years, p = 0.02). PIK3CA mutation correlated with shorter PFS (median 6.9 vs. 12.4 months, p = 0.01) and OS (median 21.2 vs. 24.2 months, p = 0.049) in multivariate analysis. A significant association between PIK3CA mutation and more disseminated disease at diagnosis, as defined by gliomatosis, multicentric lesions, or distant leptomeningeal lesions, was observed (46.2% vs. 11.1%, p = 0.004). In conclusion, despite the association with younger age, PIK3CA activating mutations are associated with earlier recurrence and shorter survival in adult glioblastoma. The aggressive course of these tumors may be related to their propensity for disseminated presentation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-019-0720-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6487518
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64875182019-06-05 PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma Tanaka, Shota Batchelor, Tracy T. Iafrate, A. John Dias-Santagata, Dora Borger, Darrell R. Ellisen, Leif W. Yang, Daniel Louis, David N. Cahill, Daniel P. Chi, Andrew S. Acta Neuropathol Commun Research Phosphatidylinositol 3-kinase signaling promotes cell growth and survival and is frequently activated in infiltrative gliomas. Activating mutations in PIK3CA gene are observed in 6–15% of glioblastomas, although their clinical significance is largely undescribed. The objective of this study was to examine whether PIK3CA mutations are associated with a specific clinical phenotype in glioblastoma. We retrospectively reviewed 157 consecutive newly diagnosed glioblastoma patients from December 2009 to June 2012 who underwent molecular profiling consisting of targeted hotspot genotyping, fluorescence in situ hybridization for gene amplification, and methylation-specific PCR for O(6)-methylguanine-DNA methyltransferase promoter methylation. Molecular alterations were correlated with clinical features, imaging and outcome. The Cancer Genome Atlas data was analyzed as a validation set. There were 91 males; median age was 58 years (range, 23–85). With a median follow-up of 20.9 months, median progression-free survival (PFS) and estimated overall survival (OS) were 11.9 and 24.0 months, respectively. Thirteen patients (8.3%) harbored PIK3CA mutation, which was associated with younger age (mean 49.4 vs. 58.1 years, p = 0.02). PIK3CA mutation correlated with shorter PFS (median 6.9 vs. 12.4 months, p = 0.01) and OS (median 21.2 vs. 24.2 months, p = 0.049) in multivariate analysis. A significant association between PIK3CA mutation and more disseminated disease at diagnosis, as defined by gliomatosis, multicentric lesions, or distant leptomeningeal lesions, was observed (46.2% vs. 11.1%, p = 0.004). In conclusion, despite the association with younger age, PIK3CA activating mutations are associated with earlier recurrence and shorter survival in adult glioblastoma. The aggressive course of these tumors may be related to their propensity for disseminated presentation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-019-0720-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-29 /pmc/articles/PMC6487518/ /pubmed/31036078 http://dx.doi.org/10.1186/s40478-019-0720-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tanaka, Shota
Batchelor, Tracy T.
Iafrate, A. John
Dias-Santagata, Dora
Borger, Darrell R.
Ellisen, Leif W.
Yang, Daniel
Louis, David N.
Cahill, Daniel P.
Chi, Andrew S.
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
title PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
title_full PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
title_fullStr PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
title_full_unstemmed PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
title_short PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
title_sort pik3ca activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487518/
https://www.ncbi.nlm.nih.gov/pubmed/31036078
http://dx.doi.org/10.1186/s40478-019-0720-8
work_keys_str_mv AT tanakashota pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT batchelortracyt pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT iafrateajohn pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT diassantagatadora pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT borgerdarrellr pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT ellisenleifw pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT yangdaniel pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT louisdavidn pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT cahilldanielp pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma
AT chiandrews pik3caactivatingmutationsareassociatedwithmoredisseminateddiseaseatpresentationandearlierrecurrenceinglioblastoma